XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure        
Pay vs Performance Disclosure, Table
As required by Item 402(v) of Regulation S-K, we are providing the following information regarding the relationship between executive compensation and our financial performance for each of the last three completed fiscal years. In determining the “compensation actually paid” to our named executive officers, we
are required to make various adjustments to amounts that have been previously reported in the Summary Compensation Table in previous years, as the SEC’s valuation methods for this section differ from those required in the Summary Compensation Table. The table below summarizes compensation values both previously reported in our Summary Compensation Table, as well as the adjusted values required in this section for the 2020, 2021, 2022, and 2023 calendar years. The compensation reported is an average for all of our named executive officers other than our principal executive officer.
Year
Summary Compensation Table Total for PEO (1)
Compensation Actually Paid to PEO (3) (4)
Average Summary Compensation Table Total for Non-PEO NEOs (2)
Average Compensation Actually Paid to Non-PEO NEOs (3) (4)
Value of Initial Fixed $100 Investment Based on
Net Income (Loss)
(in thousands)
U.S. Revenue
(in thousands) (7)
DCPH Total Shareholder Return(5)
Peer Group Total Shareholder Return (5) (6)
2023$6,010,712 $5,464,654 $2,160,242 $2,199,108 $28.26 $91.84 $(194,942)$121,546 
2022$3,554,485 $8,973,553 $1,352,930 $2,798,275 $28.72 $88.53 $(178,931)$97,216 
2021$9,414,654 $(8,237,764)$3,222,924 $(1,895,123)$17.12 $99.37 $(299,964)$81,476 
2020$7,794,944 $3,746,626 $2,357,955 $1,772,876 $91.69 $125.69 $(266,489)$37,989 
      
Company Selected Measure Name revenue in the U.S      
Named Executive Officers, Footnote In 2023, 2022, 2021, and 2020 our principal executive officer was Steven L. Hoerter.
(2)In 2023, our other named executive officers were Thomas P. Kelly, Matthew L. Sherman, M.D., Daniel L. Flynn, Ph.D., Dashyant Dhanak, Ph.D., and Daniel C. Martin. In 2021 and 2022, our other named executive officers were Thomas P. Kelly, Matthew L. Sherman, M.D., Daniel L. Flynn, Ph.D., and Daniel C. Martin. In 2020, our other named executive officers were Thomas P. Kelly, Matthew L. Sherman, M.D., Daniel L. Flynn, Ph.D., Daniel C. Martin, and Stephen B Ruddy, Ph.D.
      
Peer Group Issuers, Footnote Reflects cumulative total shareholder return of the Nasdaq Biotechnology Index, as of December 31, 2023, weighted according to the constituent companies’ market capitalization at the beginning of each period for which a return is indicated. The Nasdaq Biotechnology Index is the peer group used by the Company for purposes of Item 201(e) of Regulation S-K under the Exchange Act in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.      
PEO Total Compensation Amount $ 6,010,712 $ 3,554,485 $ 9,414,654 $ 7,794,944
PEO Actually Paid Compensation Amount $ 5,464,654 8,973,553 (8,237,764) 3,746,626
Adjustment To PEO Compensation, Footnote The following table summarizes the adjustments made in accordance with Item 402(v) of Regulation S-K in order to determine the compensation amounts shown as being “Actually Paid” in the table above:
2023202220212020
AdjustmentsPEOAverage Non-PEO NEOsPEOAverage Non-PEO NEOsPEOAverage Non-PEO NEOsPEOAverage Non-PEO NEOs
Total Compensation from Summary Compensation Table$6,010,712 $2,160,242 $3,554,485 $1,352,930 $9,414,654 $3,222,924 $7,794,944 $2,357,955 
Adjustments for stock option and restricted stock awards
(Subtraction): Summary Compensation Table Stock Award Amounts and Option Award Amounts(4,772,100)(1,438,222)(2,311,965)(574,162)(8,402,574)(2,566,220)(6,597,306)(1,642,525)
Addition: Fair value at year end of equity awards granted during the covered fiscal year that are outstanding and unvested at year end2,409,628 1,283,255 4,139,605 1,078,617 2,412,177 853,115 5,621,499 1,461,294 
Addition (Subtraction): Year-over-year change in fair value of equity awards granted in any prior fiscal year that are outstanding and unvested at year end51,931 4,708 1,867,341 586,710 (9,301,993)(2,497,620)(913,426)(279,492)
Addition: Vesting date fair value of equity awards granted and vesting during such year2,132,494 259,426 976,429 176,855 809,790 180,286 1,325,624 264,075 
Addition (Subtraction): Change as of the vesting date (from the end of the prior fiscal year) in fair value of equity awards granted in any prior fiscal year for which vesting conditions were satisfied during such year(368,011)(70,301)747,658 177,325 (3,169,818)(1,087,608)(3,484,709)(388,431)
Compensation Actually Paid (as calculated)$5,464,654 $2,199,108 $8,973,553 $2,798,275 $(8,237,764)$(1,895,123)$3,746,626 $1,772,876 
      
Non-PEO NEO Average Total Compensation Amount $ 2,160,242 1,352,930 3,222,924 2,357,955
Non-PEO NEO Average Compensation Actually Paid Amount $ 2,199,108 2,798,275 (1,895,123) 1,772,876
Adjustment to Non-PEO NEO Compensation Footnote The following table summarizes the adjustments made in accordance with Item 402(v) of Regulation S-K in order to determine the compensation amounts shown as being “Actually Paid” in the table above:
2023202220212020
AdjustmentsPEOAverage Non-PEO NEOsPEOAverage Non-PEO NEOsPEOAverage Non-PEO NEOsPEOAverage Non-PEO NEOs
Total Compensation from Summary Compensation Table$6,010,712 $2,160,242 $3,554,485 $1,352,930 $9,414,654 $3,222,924 $7,794,944 $2,357,955 
Adjustments for stock option and restricted stock awards
(Subtraction): Summary Compensation Table Stock Award Amounts and Option Award Amounts(4,772,100)(1,438,222)(2,311,965)(574,162)(8,402,574)(2,566,220)(6,597,306)(1,642,525)
Addition: Fair value at year end of equity awards granted during the covered fiscal year that are outstanding and unvested at year end2,409,628 1,283,255 4,139,605 1,078,617 2,412,177 853,115 5,621,499 1,461,294 
Addition (Subtraction): Year-over-year change in fair value of equity awards granted in any prior fiscal year that are outstanding and unvested at year end51,931 4,708 1,867,341 586,710 (9,301,993)(2,497,620)(913,426)(279,492)
Addition: Vesting date fair value of equity awards granted and vesting during such year2,132,494 259,426 976,429 176,855 809,790 180,286 1,325,624 264,075 
Addition (Subtraction): Change as of the vesting date (from the end of the prior fiscal year) in fair value of equity awards granted in any prior fiscal year for which vesting conditions were satisfied during such year(368,011)(70,301)747,658 177,325 (3,169,818)(1,087,608)(3,484,709)(388,431)
Compensation Actually Paid (as calculated)$5,464,654 $2,199,108 $8,973,553 $2,798,275 $(8,237,764)$(1,895,123)$3,746,626 $1,772,876 
      
Equity Valuation Assumption Difference, Footnote The fair value of stock options included in compensation actually paid is estimated using a Black-Scholes option pricing model in accordance with the SEC rules. This model uses both historical data and current market data to estimate the fair
value of options and requires several assumptions. The range of assumptions used in estimating the fair value for the stock options included in compensation actually paid during 2023, 2022, 2021, and 2020 are as follows:
2023202220212020
Risk-free interest rate3.39-4.88%1.35 - 4.33%0.50 - 1.39%0.30 - 1.75%
Expected term (in years)5.50 - 6.25 years5.50 - 6.25 years5.50 - 6.25 years5.50 - 6.25 years
Expected volatility81.8 - 87.7%76.7 - 82.8%73.1 - 81.1%72.2 - 81.1%
Expected dividend yield0%0%0%0%
      
Compensation Actually Paid vs. Total Shareholder Return
The chart below represents a comparison of the compensation actually paid to our principal executive officer and the average compensation “actually paid” to our other named executive officers set forth in the
Pay versus Performance table above, as compared against the following performance measures: (1) our cumulative total shareholder return (“TSR”), (2) the Nasdaq Biotechnology Index (“NBI”) total shareholder return, (3) our net loss, and (4) our total U.S revenue in 2023. The chart below also represents a comparison of our TSR against our peer group (NBI) TSR. For purposes of comparison, each of the metrics in the chart has been presented on a scaled basis, assuming an initial starting value of $100 in each instance.
4805
      
Compensation Actually Paid vs. Net Income
The chart below represents a comparison of the compensation actually paid to our principal executive officer and the average compensation “actually paid” to our other named executive officers set forth in the
Pay versus Performance table above, as compared against the following performance measures: (1) our cumulative total shareholder return (“TSR”), (2) the Nasdaq Biotechnology Index (“NBI”) total shareholder return, (3) our net loss, and (4) our total U.S revenue in 2023. The chart below also represents a comparison of our TSR against our peer group (NBI) TSR. For purposes of comparison, each of the metrics in the chart has been presented on a scaled basis, assuming an initial starting value of $100 in each instance.
4805
      
Compensation Actually Paid vs. Company Selected Measure
The chart below represents a comparison of the compensation actually paid to our principal executive officer and the average compensation “actually paid” to our other named executive officers set forth in the
Pay versus Performance table above, as compared against the following performance measures: (1) our cumulative total shareholder return (“TSR”), (2) the Nasdaq Biotechnology Index (“NBI”) total shareholder return, (3) our net loss, and (4) our total U.S revenue in 2023. The chart below also represents a comparison of our TSR against our peer group (NBI) TSR. For purposes of comparison, each of the metrics in the chart has been presented on a scaled basis, assuming an initial starting value of $100 in each instance.
4805
      
Tabular List, Table
The following is a tabular list of the seven most important performance measures in 2023, including our financial performance measure, that we use to link compensation actually paid to our named executive officers, and appear in no particular order:
1
Maximize the value of QINLOCK for patients and stockholders and initiate the INSIGHT study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18;
2Rapidly advance vimseltinib in our Phase 3 MOTION study in TGCT;
3Advance DCC-3116 in clinical development;
4Advance our research pipeline;
5
Invest in our culture and enable future growth;
6
Achieve U.S. revenue target; and
7
Achieve European revenue target.
      
Total Shareholder Return Amount $ 28.26 28.72 17.12 91.69
Peer Group Total Shareholder Return Amount 91.84 88.53 99.37 125.69
Net Income (Loss) $ (194,942,000) $ (178,931,000) $ (299,964,000) $ (266,489,000)
Company Selected Measure Amount 121,546,000 97,216,000 81,476,000 37,989,000
PEO Name Steven L. Hoerter Steven L. Hoerter Steven L. Hoerter Steven L. Hoerter
Additional 402(v) Disclosure Value assumes $100 invested on December 31, 2019The Company has identified revenue in the U.S. as the Company-Selected Measure for the pay versus performance disclosure, as it represents the most important financial performance measure used to link compensation actually paid to the Chief Executive Officer and the other named executive officers to the Company’s performance. For additional information about performance measures, see the discussion under “Tabular List” below.      
Measure:: 1        
Pay vs Performance Disclosure        
Name Maximize the value of QINLOCK for patients and stockholders and initiate the INSIGHT study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18;      
Measure:: 2        
Pay vs Performance Disclosure        
Name Rapidly advance vimseltinib in our Phase 3 MOTION study in TGCT;      
Measure:: 3        
Pay vs Performance Disclosure        
Name Advance DCC-3116 in clinical development;      
Measure:: 4        
Pay vs Performance Disclosure        
Name Advance our research pipeline;      
Measure:: 5        
Pay vs Performance Disclosure        
Name Invest in our culture and enable future growth;      
Measure:: 6        
Pay vs Performance Disclosure        
Name Achieve U.S. revenue target; and      
Measure:: 7        
Pay vs Performance Disclosure        
Name Achieve European revenue target.      
PEO | Stock Awards & Options Total Value Member [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ (4,772,100) $ (2,311,965) $ (8,402,574) $ (6,597,306)
PEO | Equity Awards Granted in Current Year Reported Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 2,409,628 4,139,605 2,412,177 5,621,499
PEO | Equity Awards Granted in Prior Year Change in Reported Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 51,931 1,867,341 (9,301,993) (913,426)
PEO | Equity Awards Granted in Current Year Vested Date Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 2,132,494 976,429 809,790 1,325,624
PEO | Equity Awards Granted in Prior Year Vested Change in Reported Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (368,011) 747,658 (3,169,818) (3,484,709)
Non-PEO NEO | Stock Awards & Options Total Value Member [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (1,438,222) (574,162) (2,566,220) (1,642,525)
Non-PEO NEO | Equity Awards Granted in Current Year Reported Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,283,255 1,078,617 853,115 1,461,294
Non-PEO NEO | Equity Awards Granted in Prior Year Change in Reported Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 4,708 586,710 (2,497,620) (279,492)
Non-PEO NEO | Equity Awards Granted in Current Year Vested Date Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 259,426 176,855 180,286 264,075
Non-PEO NEO | Equity Awards Granted in Prior Year Vested Change in Reported Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ (70,301) $ 177,325 $ (1,087,608) $ (388,431)